Table 2.
Participants’ demographics and details across the different analgesics used
| Factor | APAP | p value | NSAIDs | p value | Hot comprises | p value | Herbals | p value | Rx of central medications | p value |
|---|---|---|---|---|---|---|---|---|---|---|
| Age | ||||||||||
| Below 35 years | 100 (45.2%) | 0.06 | 25 (31.6%) | < 0.001* | 14 (33.3%) | 0.03* | 44 (41.5%) | 0.06 | 10 (17.9%) | < 0.001* |
| 35 years and above | 121 (54.8%) | 54 (68.4%) | 28 (66.7%) | 62 (58.5%) | 46 (82.1%) | |||||
| Marital status | ||||||||||
| Single | 50 (22.6%) | 0.05 | 18 (22.8%) | 0.3 | 13 (31%) | 0.05 | 22 (20.8%) | 0.5 | 15 (26.8%) | 0.12 |
| Married | 171 (77.4%) | 61 (77.2%) | 29 (69%) | 84 (79.2%) | 41 (73.2%) | |||||
| Education | ||||||||||
| Below high school | 133 (60.2%) | 0.008* | 41 (51.9%) | 0.23 | 30 (71.4%) | 0.02* | 63 (59.4%) | 0.22 | 36 (64.3%) | 0.11 |
| High school and above | 88 (39.8%) | 38 (48.1%) | 12 (28.6%) | 43 (40.6%) | 20 (35.7%) | |||||
| Residence | ||||||||||
| Amman | 91 (41.2%) | 0.37 | 38 (48.1%) | 0.12 | 20 (47.6%) | 0.26 | 41 (38.7%) | 0.45 | 16 (28.6%) | 0.03* |
| Peripheries | 130 (58.8%) | 41 (51.9%) | 22 (52.4%) | 65 (61.3%) | 40 (71.4%) | |||||
| Body mass index | ||||||||||
| 25 and below | 61 (27.6%) | 0.49 | 11 (13.9%) | < 0.001* | 11 (26.2%) | 0.48 | 24 (22.6%) | 0.09 | 7 (12.5%) | 0.002* |
| Above 25 | 160 (72.4%) | 68 (86.1%) | 31 (73.8%) | 82 (77.4%) | 49 (87.5%) | |||||
| Chronic diseases | ||||||||||
| No | 69 (31.2%) | 0.02* | 19 (24.1%) | 0.01* | 6 (14.3%) | 0.001* | 31 (29.2%) | 0.08 | 7 (12.5%) | < 0.001* |
| Yes | 152 (68.8%) | 60 (75.9%) | 36 (85.7%) | 75 (70.8%) | 49 (87.5%) | |||||
| Fibromyalgia | ||||||||||
| Below threshold | 124 (56.1%) | 0.19 | 31 (64.6%) | < 0.001* | 24 (57.1%) | 0.53 | 54 (50.9%) | 0.05 | 22 (39.3%) | 0.002* |
| Above threshold | 97 (43.9%) | 48 (60.8%) | 18 (42.9%) | 52 (49.1%) | 34 (60.7%) | |||||
| Severe insomnia | ||||||||||
| Below threshold | 97 (43.9%) | 0.23 | 24 (30.4%) | < 0.001* | 15 (35.7%) | 0.11 | 42 (39.6%) | 0.09 | 11(19.6%) | < 0.001* |
| Above threshold | 124 (56.1%) | 55 (69.6%) | 27 (64.3%) | 64 (60.4%) | 45 (80.4%) | |||||
| Severe depression | ||||||||||
| Below threshold | 94 (42.5%) | 0.33 | 20 (25.3%) | < 0.001* | 12 (28.6%) | 0.04* | 39 (36.8%) | 0.13 | 11 (19.6%) | < 0.001* |
| Above threshold | 57 (57.5%) | 59 (74.7%) | 30 (71.4%) | 67 (63.2%) | 45 (80.4%) |
Chi-square analysis to examine the association between the participants’ factors and the different analgesics used. Fibromyalgia symptoms was assessed using Patient self-report survey for the assessment of fibromyalgia with a cut-off score of 13 consistent with fibromyalgia burden. Insomnia severity was measured using the Insomnia severity index with a cut-off score of 14 for severe insomnia. Depression was measured using the Patient Health Questionnaire (PHQ-9) with a cut-off score of 14 for severe depression
APAP acetaminophen, NSAIDs nonsteroidal anti0inflammatory drugs
*p < 0.05